https://www.physiology.org/professional-development/meetings-events/american-physiology-summit?SSO=Y

It seems everyone is holding firmly to their shares and wont really trade anything until it goes back on a tier that is accessible to everyone then the chase will be on. GLTA

Congrads Jeff and all of RSPI


Thu, Apr 03, 2025
Home » Biopharma grants in 2024
Special Report

US DOD to award funding to manufacture and formulate the clinical material for Respirerx's CX-1739 phase II study against spinal cord injury

They did say that the aduits info was approx 80% and that they would be keeping up with it how much they didnt say, but as you stated their hasnt been much that we know of that would prevent them when funding is available a 3-6 week window should be doable. It is tax season and that could play a roll in the speed it will get done if it is soon. Hopefully Jeff will have news that will be positive and a clear pathway they are going and not info that is grey and leaving all of us to try to put the puzzle together with a few of the piece laying under the table that we don't see. HAHAHA GLTA

I reached out to the funding agent helping ResolutionRX a few days back got a reply here is the basic of the reply, there are conversations regarding funding with potential parties, however as this information is confidential, they can’t say much more than that at this time. Sounds like they are atleast moving in a positive direction with interest . GLTA

Just checked and all my shares are now long term, let the fun begin . Hopefully they have good news to share when they do put out news. GLTA

I sent a letter to the SEC asking a few question concerning RSPI and the same question about address of a single share holder or multiple at that address count as one . I have not gotten a email back yet answering the question instead when I sent it to the Commissioner I got this back

Good morning,

Thank you for reaching out. All tips, complaints, or referrals can be submitted using our online form found here: https://www.sec.gov/tcr. If you are a whistleblower and would like to submit information to the Commission, you may do so here: https://www.sec.gov/whistleblower. If you have questions you’d like to discuss, you can contact the Office of Investor Education and Advocacy at 1-800-732-0330 or by email at help@sec.gov.

Office of Commissioner Hester M. Peirce

100 F Street, NE

Washington, DC 20549

then i sent this back to her Thank you for the reply , i sent a question in thru the form process over a month ago same question still no answer. Thank you

then this back to her still nothing . I think the question should be a very simple answer to reply to , I guess Jeff was correct when he said he reached out and has not heard back from SEC.

Here is the reply I got from Jeff Great questions. Most if not all will be addressed in the next update. GLTA

Hey Jeff here is a few more takes on everything could you include some answers if you can in your update that you are working on. Thank you

While in my opinion KRM-ll-81 has the most potential with superior preclinical profile to address the large unmet markets of epilepsy and pain management. Quite possibly a blockbuster asset....

Respire sure does publish alot related to the ampakine platform. I am curious to understand what are the hurdles related to initiating this phase 2 SCI clinical as well as what is the target for further grant applications for the ampakine program per the shareholder letter? I wonder if they are finally looking to move into ADHD clinicals which their efforts related to this medical indication (again large unmet need) are continually mentioned in their past presentations as well as publication efforts. And if they are moving forward, would it be with CX-1739 or CX-717 or another amapkine?

This just highlights why many of us invested here believe things will snowball significantly and allow them to pursue many clinical pathways simultaneously once they ink that first major funding or BP deal. Excited to see these assets turn the page and begin a new chapter... Can only watch and wait..


LT - I recall during the Cortex days that a phase 2 trial for CX717 for ADHD has been done which resulted in truly extraordinary efficacy without side effects by other medications. The FDA torpedoed upon application for a phase 3 by that flawed histological result which was later shown (2018) to be a fixation problem, no question. So the ADHD phase 2 has been done. Doesn't that mean a phase 3 trial? If so, big pharma will have to finance. I don't understand why RSPI hasn't touted that ADHD trial result.


" I don't understand why RSPI hasn't ".....

If we understood, we wouldn't need this support group/forum...lol Not sure what they expected when they went to the EM and why they clearly want to stay in the shadows...

Then again, maybe after spending countless hours reading all the publications and competitor related publications and connecting the dots, maybe we actually do understand. I hope we can get to a point some day where we on this forum can discuss the merits of this clinical trial or that clinicial pathway and not, why RSPI hasn't....


"Then again, maybe after spending countless hours reading all the publications and competitor related publications and connecting the dots, maybe we actually do understand." Last week I came across one of the early UCI ampakine publications that has now been cited over 300 times! Where the hell has all those papers been published? That has got to be a record. Of course, with the limited recourses that RSPI has up to now, just keeping up with the literature and writing summary papers is a monumental task in itself! I'm a bit surprised that Jeff even has time to deal with us stockholders. To me going into EM is a no brainer - no distractions having to deal with all those pesky filings when a catch up is possible later in this game. Right?


LMAO, no it is not a no brainer and is unacceptable.

Every pharma company I have followed can keep up with their SEC filings just fine and both present and leverage premier assets for funding and forward progress to gather the necessary partners and resources... Going on 18 months without a filing and on the EM for 9 months.


It's litteraly no benefit for them to stay on Em anyone who says otherwise is coping with the situation. All the payments and salary is depended on stock performance reliant on PPS rasing substantially.


The speculative themes or excuses for reasons they are still on the EM is they are negotiating a deal or two. Does the EM provide that leverage or clarity?

All I know is it feels like they are wasting time. Look at Incannex and their progress with OSA and dronabinol. Look at Saniona and their progress with multiple gabakines, one which has huge deal with Acadia.

Competition is only going to accelerate

Very Interesting read maybe Jeff will shed some light if it is them and he can.

Hopefully he gets the material together and puts out a detailed update on everything. GLTA Enjoy your weekend everyone

Thanks but we all are helping each other thru this murky times. Hopefully we get some positive news and or updates when he does release it to us. GLTA

Here is what I sent to Jeff , and ask him for updates on the items that have been brought up on thiis board , it apperas that the red highlights didnt carry over from Email. But it was all the key things that we are all waiting on. Hopefully he can address them in his up coming progress. Have a great day GLTA

. Hello

The upcoming updates you are working on , can you read the below statements from shareholders and include updates on the items people have touched on. There are a few items that should have results good or bad from when we were told the trial stage they were in almost a year ago. It would be nice to hear on the items in Red as part of whatever you were going to update us on also. Thank you

They basically have stated they need additional funds to push the ampakine platform and SCI phase2 forward as well as additional funding for OSA platform which is also stalled for other reasons apparently since some funding is secured there but not yet able to be utilized.

So that really leaves their crown jewel KRM-ll-81 which is deep into NIH IND enabling studies, which supposedly in tier 3 well over a year now, so one would think with the accelerated intent of the NIH HEAL program that the preclincal effort should be almost completed. They need BP support to go into clinicals and would need to strike deals (license, partnership, sale has been their theme!), which judging by competitor activity with gabakine candidates that are similar and likely inferior to KRM-ll-81 that should be a no brainer. Just a matter of timing and who and what, IMO. I don't like this do nothing approach with the EM and presentation/communication, etc. My opinion is time is money and wasted time not building something of value is ridiculous. Even with timetables of preclinical efforts, I would think prepping your presentation and building resources including more stakeholders would be of value. The CSO and the science team here are extremely reputable and the assets, especially the selectivity profile of KRM-ll-81 is outstanding. So we wait on the beach.
Neuromodulators: This includes GABAkines and AMPAkines, which are proprietary chemical entities designed to positively modulate GABAA receptors and AMPA-type glutamate receptors, respectively. These compounds aim to address disorders caused by disruptions in neuronal signaling. For example, their lead GABAkine has shown preclinical promise in pain relief, and their AMPAkine CX1739 is being studied for safety and efficacy in a Department of Defense-funded Phase 2 clinical trial announced in May 2024.

Pharmaceutical Cannabinoids: This platform includes dronabinol, a synthetic cannabinoid that interacts with the body’s endogenous cannabinoid receptors. RespireRx has established ResolutionRx Ltd., an Australian subsidiary formed in January 2023, to advance its obstructive sleep apnea drug development program.

Recent updates from RespireRx include a February 2025 letter from its CFO and CEO to stockholders and stakeholders, highlighting progress in their drug development efforts.

Additionally, the company has made strides in its leadership, appointing Dr. Dariusz Naziek to its board of directors in January 2024. RespireRx trades on the OTC Pink Market under the ticker symbol RSPI.

For the latest developments, such as specific clinical trial outcomes or financial performance, further details would typically be found in their SEC filings, like the Form 10-Q from September 2023 or the yet-to-be-filed 2023 annual report (Form 10-K). However, based on available information, RespireRx remains a small player in the biotech space, focusing on novel approaches to challenging medical conditions.

I am not sure anyone disagrees with this comment....

"They have a fiduciary duty and obligation to shareholders and they aren't meeting it."

It is clear to me that they have something significant and quite possibily "breakthrough" level candidate with KRM-ll-81. One only has to read the commentary in their publications as well as competitor publications and activity and it suggests that KRM-ll-81 might just have the superior preclinical selectivity profile for gabakines. And of course harken back to the CSO interview related to this announcement and the move into tier 3 NIH HEAL program and easily the excitement is there from the CSO! They have and apparently continue to struggle to get traction for both the OSA program and ampakine platform even with the DOD funding hanging out there. Both have potential, but that has been known for a long time and stalled for various reasons I assume. All this talk about creating preferred and phantom shares as well as moving to institutional and insider support with attached warrants all started however when the gabakine got traction with the NIH. So, they have huge equity linked to success here which is great.

I think the consternation centers around being on the OTC and now the EM of all places with an abandonment of the website and lack of professional tact with presentation and communications. Does this approach get the best deals for any assets? Does this approach attract the needed resources? I don't know, maybe I am too much of a purest and do the right thing mentality. I probably should just focus my energy elsewhere and just smile and wave when they sign a huge deal sooner or later and this thing runs wild past .10, .20, .30 like so many storied pharma stocks of the OTC and NASDAQ for that matter. And really the thing is, this one may actually have something very premier backing their story! Good luck to all of us investors and our little support group here

Sent asking about Any updates Jeff could put out to the masses, a rough timeline to get this back trading , up dates on the IND , trials ?
Reply
They should have some updates shortly. Not with respect to trading, but with respect to other matters. GLTA

https://www.msn.com/en-us/money/markets/d-wave-stock-is-falling-why-nvidia-s-quantum-computing-event-hurt-the-shares/ar-AA1Bn4Lq?ocid=hpmsn&cvid=2a90c52b455f4cc8d30bbc1510a659d0&ei=45

https://pitchbook.com/profiles/company/41040-55#overview

This is a nice read along with a huge sell of shares at 12.25 per share https://www.msn.com/en-us/money/companies/quantum-computing-inc-qubt-one-of-the-best-quantum-computing-stocks-to-buy-right-now/ar-AA1B6kUJ?ocid=hpmsn&cvid=7e31e2f3d8fc4825f29a4d00139c4c51&ei=12

https://www.msn.com/en-us/money/topstocks/we-asked-retail-traders-their-top-quantum-stock-d-wave-leads-the-pack-followed-by-rigetti/ar-AA1B3tnG?ocid=hpmsn&cvid=e37a959150664d90f48333908a1fc083&ei=59

It would be nice to be back trading and seeing this RSPI have days like Friday on another stock I have 9.96 3.05 (44.14%) GLTA

Nice buying time at theses prices. Slowly building a stake here . GLTA

#6 - D-Wave Quantum (NYSE:QBTS)
D-Wave Quantum Inc. (NYSE: QBTS) is the last of the pure-play quantum computing stocks on this list. The company’s claim to fame is that it was the first to develop a working 28-bit quantum computer.

In 2011, D-Wave pioneered its quantum annealing technology, which led to the world’s first commercially available quantum computer system—priced at $10 million.

Unlike a traditional gate-based system, D-Wave's quantum annealing technology analyzes the qubit and finds its optimal state or “ground state” where it will be the most stable to perform the needed calculations. Today, the company offers this technology via cloud-based access or on-premise systems for enterprise customers.

Still, like the other pure-play quantum computing stocks on this list, D-Wave is a small company, with a market cap of around $1.4 billion. It has very little revenue coming in and is not profitable. Despite this, the stock has attracted significant analyst attention. Of the six analysts covering it, all have given QBTS sock a Strong Buy rating.

Maybe a buyout with a cause that they stay aboard to run the trials, and see it thru.

It would help them alot to come out and say they have NDA's in place. That alone would would speak volume to the shareholder IMO. It is completely legal to say they are involved in NDA(s) . GLTA

Hey Doc I asked a while back , do you see that I signed up for this? Could you let me know if you see my info thank you

An interesting read , I know it is not RSPI just that things are moving for pain relief . GLTA
https://www.msn.com/en-us/health/other/compound-mimics-cannabis-for-pain-relief-without-the-side-effects-mouse-study-points-to-effective-opioid-alternative/ar-AA1Ajt09?ocid=hpmsn&cvid=9777833c564f4560c42530cedf7e6ceb&ei=35

It is a most puzzling direction and course to get there for sure . GLTA

What type of time period are they thinking before it is ? Not an exact date but time range . thanks

That is exactly what I just got back . GLTA

I hear you , maybe write Jeff and vent your frustration , question about form 15 and see what he replies with. I just went back to see when my holding started here 3/7/2024 for 9m and the other 6m will be a year over the next 20 days. Yes it has been along wait without being able to see how this would have traded over the last year basically. Hopefully the wait is coming to an end , or maybe we look at our account one day and it has a # with a bunch of Zeros behind it and no shares in it . GLTA

Yes a very intereting buy , I thought this board was dead , noone talking about anything. Glad to hear someone is watching. New to the board and postion. GLTA

Thank you for update I can't believe you didnt know about the OTC changes coming , were you still looking at going back on OTC or other irons in the fire currently going on , anything on the A/S O/S structure and anything on the progress or lack of for ResolutionRX

He said Yes they are still looking to start trading again on the OTC. and that many irons in the fire as well.

This is from over seas , I asked if any updates ect..

He said he caught up with Jeff end of January and is due a catch up with him in the coming weeks. There have been no updates as yet.

I guess we will just have to see when it happens GLTA

Yes I had the same thought about not aware of changes coming for OTC , I hope he gets back with current share structure if he does will pass on , I am thinking about reashing out to the overseas fund investor to see how that is going and see if they have had any luck. Last I talked to him they were still working on things, he did see my point about the look the overall company is presenting and how would people want to invest in an EM company without seeing progress or bigger backers aboard. GLTA

This is what I got back from Jeff on a few questions I asked , About any news from SEC , asked about A/S and O/S and all share structure , and sent him a copy
( According to recent information, the OTC market, specifically the "Pink Current" tier, is set to change on July 1, 2025, transitioning to a new market called "OTC ID" (OTC Identifier). This change will involve new disclosure requirements for companies listed on the OTC market.
Key points about the change:
New market name: "OTC ID"
Date of change: July 1, 2025
Impact on companies: Companies that do not meet the new disclosure standards may be moved to a different market tier like "Pink Limited" or "Expert Restricted". ) asking about the upcoming OTC changes .

No response from the SEC after several outreaches.
He is not sure yet about the impact of the OTC market changes. He will need to find out more about the specifics of achieving OTC ID.He will get back to me after he has done some more work.
GLTA

https://www.msn.com/en-us/money/companies/dear-d-wave-stock-fans-mark-your-calendars-for-march-13/ar-AA1AeNA6?ocid=hpmsn&cvid=6242e5c7d0b74774ee947c0c54224723&ei=49

If you are using Etrade you can only set a sell order one day at a time while on EM it won't allow a 60 day sell order. Check your trading platform . GLTA

Looking good , I would love 7.22 a share here. GLTA

Last time I hit Jeff up , they were waiting to hear back from the SEC .

Not sure if it is out the window, I just recalled that info. Maybe when he stated that it was just the start of the EM and they thought they were not going to be on it long. If someone wanted to go back that far I am pretty sure I posted it. I think they know they need to do something for the shareholders and the company to trade again. You can't expect an investor to be hyped to invest in a company on the EM. Maybe the new OTC rules is what they are waiting on to just drop all the necessary filings to enter that tier. All a guess at this point, Jeff wont say to much on the direction due to insider information just points back at the last filing for info. GLTA

Yes it will , I can't remember exactly when but I remember talking to Jeff awhile back right around the time they went to the EM and suggested alternative reporting and if I recall he said it would cost just about the same to do that as it would for regular reporting. I am pretty sure I posted that back then. I really don't know what they have plan for themselves and us but I think they are working on it. I think June timeframe would be a good time to start seeing something start moving in a positive direction. IMO GLTA

Yes, the NIH helps facilitate partnerships for assets that complete the NIH Preclinical Screening Platform for Pain (PSPP) program. The NIH PSPP program staff work with the asset owner to negotiate a participant agreement that outlines the legal parameters of the partnership.

Yes everyday I have to put that 1.6m up , Etrade wont do a good to close or 60 days since it is on the EM . Volume wont happen on the EM , unless pending news gets out but if that happens I dont see the USA shareholders letting go for cheapies at that point.

GLTA